Trypanosoma brucei

Trypanosoma brucei is a complex species of parasitic kinetoplastid found in sub-Saharan Africa. Unlike many other protozoan parasites, it does not live inside host cells. Instead, it is exclusively extracellular, meaning it lives in the blood plasma and other body fluids. This parasite is responsible for causing two deadly vector-borne diseases. In humans, the infection is known as African trypanosomiasis, or sleeping sickness. In animals like cattle and horses, the disease is called nagana.

The parasite moves between mammal hosts using an insect vector called the tsetse fly, or Glossina. Transmission occurs when the fly bites a host to take a blood meal. During this process, the parasite moves from the fly into the mammal, or vice versa. The parasite undergoes complex morphological changes, which are changes in shape and structure, to survive these different environments. Once in the mammalian bloodstream, the parasite uses a clever survival method called antigenic variation. It uses variant surface glycoproteins on its cell surface to constantly change its appearance. This allows it to evade the host's adaptive immunity, leading to a chronic infection.

Scientists classify T. brucei as a species complex consisting of three distinct subspecies. The first is T. b. brucei, which infects non-human mammals and causes nagana. The other two are zoonotic, meaning they can infect both humans and animals. T. b. gambiense causes a slow-onset chronic form of sleeping sickness and is most common in central and western Africa. It is responsible for about 98% of all human cases and is nearly 100% fatal without treatment. The third subspecies, T. b. rhodesiense, causes a fast-onset acute form of the disease. It is prevalent in southern and eastern Africa, where game animals and livestock serve as the primary reservoir.

Humanity has observed the effects of this parasite for many centuries. Ancient Egyptian writings included descriptions of sleeping sickness in animals. In 1734, John Atkins provided the first medical description of human sleeping sickness in Guinea. Later, in 1803, Thomas Masterman Winterbottom described swollen lymph nodes in the neck, a symptom known as Winterbottom's sign. The parasite itself was discovered in 1894 by Sir David Bruce. Working at Ubombo Hill with his wife, Mary Elizabeth Bruce, he identified the parasites in the blood of diseased cows. The genus name comes from Greek words meaning "borer body," describing its corkscrew movement.

Research into the parasite's life cycle was a major scientific effort involving many teams. In 1902, a Sleeping Sickness Commission was formed to investigate an epidemic in Uganda. This epidemic was severe, with an estimated death toll of 20,000 people, and eventually killed more than 250,000 people over two decades. While early investigators struggled, David Bruce eventually established that the tsetse fly was the transmitter. Later, in 1909, Friedrich Karl Kleine discovered that the parasite has developmental stages within the fly. Finally, Muriel Robertson established how the parasites reach the salivary glands of the fly between 1911 and 1912.

At a microscopic level, T. brucei is a single-celled eukaryotic organism. It measures between 8 and 50 micrometers in length and has a streamlined, tapered body. Its cell membrane is called a pellicle, which protects organelles like the nucleus and mitochondria. A unique feature of this parasite is the kinetoplast, an organelle containing thousands of interlinked circles of mitochondrial DNA. This kinetoplast sits near the basal body, which is the starting point for the flagellum. The flagellum is a tail-like structure that allows the parasite to swim through body fluids.

Understanding T. brucei is critical because it is one of the few pathogens that can cross the blood-brain barrier. This ability to enter the central nervous system makes the disease particularly dangerous. Currently, there is an urgent need for new drug therapies. Existing treatments can have severe side effects and may even be fatal to the patient. Because the subspecies are so closely related, scientists use molecular markers to tell them apart. For example, the SRA gene helps identify T. b. rhodesiense, while the TgsGP gene is specific to certain T. b. gambiense strains.